NASDAQ:BEAM Beam Therapeutics Q3 2026 Earnings Report $25.84 +0.17 (+0.64%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Beam Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.16Beat/MissN/AOne Year Ago EPSN/ABeam Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$8.75 millionBeat/MissN/AYoY Revenue GrowthN/ABeam Therapeutics Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateWednesday, November 4, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Beam Therapeutics Earnings HeadlinesBeam Therapeutics Inc. (NASDAQ:BEAM) Stock Rated "Moderate Buy" by Sell-Side AnalystsOctober 6 at 2:15 AM | americanbankingnews.comBeam Therapeutics consensus price target decreased by 13.38% to MX$839.72October 4 at 6:14 AM | msn.comNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire year. The top five hyperscalers, Amazon, Google, Microsoft, Meta, and Oracle, are projected to spend 800 billion on AI this year and 1.3 trillion next year. Jason Bodner, a former Wall Street trader whose system has flagged stocks like Nvidia, Super Micro Computer, and Vertiv before major run ups, says a new light speed technology called Accelerated AI could be next in line for that spending.October 6 at 1:00 AM | Brownstone Research (Ad)Beam Therapeutics (NASDAQ:BEAM) Raised to Sell at Wall Street ZenOctober 3 at 1:07 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 1, 2026 | prnewswire.comBeam alleges Chinese biotech, and its U.S. partner Serapha stole trade secretsSeptember 30, 2026 | seekingalpha.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments. Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders. Its pipeline has included investigational programs such as BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia. These programs are investigational and remain subject to clinical and regulatory evaluation. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was established by scientists and entrepreneurs including David Liu, a pioneer in base-editing technology. John Evans has served as the company’s chief executive officer. Beam’s operations are centered on advancing its proprietary editing platform and developing genetic medicines for patients with serious diseases.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
